

IPCA PHARMACEUTICALS INC.

DIRECTORS' REPORT

To
The Members
Ipca Pharmaceuticals Inc.

Your Directors have pleasure in presenting their Annual Report together with the audited statement of accounts for the year ended 31st March, 2017.

FINANCIAL RESULTS

Particulars	For the year ended 31 st March 2017 (Rs. in lacs)	For the year ended 31 st March 2016 (Rs. in lacs)
Total Income	504.40	574.98
Total Expenditure	385.18	438.72
Financial Cost	0.60	7.12
Depreciation	35.21	34.62
Profit before extraordinary items and tax	83.41	94.52
Less: Provision for taxation		
Current	--	--
Deferred	--	--
Earlier Year's Tax	--	--
Profit after tax but before extraordinary items	83.41	94.52
Extraordinary Items	--	--
Other Comprehensive Income	(17.83)	29.78
Total Comprehensive Income for the period (Comprising Profit /(Loss) and Other Comprehensive Income for the period)	65.58	124.31
YOUR DIRECTORS RECOMMEND THE FOLLOWING APPROPRIATIONS		
Surplus in Profit & Loss Account as per last Balance Sheet	(308.47)	(403.00)
Net Profit for the year	83.41	94.52
Less:		
Transfer to General Reserve	--	--
Balance as at year end	(225.06)	(308.47)

INCORPORATION

The Company was incorporated under the laws of the state of New Jersey in the United States of America on 10th July, 2003. The Company is a wholly owned subsidiary of Ipca Laboratories Limited, India.

Your Company is presently coordinating the development and registration of formulations developed by the parent company in United States of America as well as distribution of Active Pharmaceutical

IPCA PHARMACEUTICALS INC.

Ingredients (APIs) manufactured by the parent company viz. Ipca Laboratories Limited in the US market.

TRANSFER TO GENERAL RESERVE

During the year under report, the Company has not transferred any amount to General Reserve Account.

OPERATIONS

The total income for the financial year under report was Rs. 504.40 lacs (Previous year Rs. 574.98 lacs) and the operations have resulted in a net profit of Rs. 83.41 lacs (Previous year net profit of Rs. 94.52 lacs). During the year under report there was no change in the nature of Company's business.

MATERIAL CHANGES AND COMMITMENTS AFTER THE END OF THE FINANCIAL YEAR

No material changes or commitments affecting the financial position of the Company have occurred between the end of the financial year to which financial statements in this report relate and the date of this report.

SHARE CAPITAL

The paid-up equity share capital of the Company as at 31st March, 2017 is Rs.920.20 lacs. The Company currently has no outstanding shares issued with differential rights, sweat equity or ESOS.

SUBSIDIARY, JOINT VENTURE AND ASSOCIATE COMPANIES

The Company does not have any subsidiary, joint venture and associate companies

DIVIDEND

In view of the carry forward loss, your Directors do not recommend any dividend for the financial year ended 31st March, 2017.

DIRECTORS' RESPONSIBILITY STATEMENT

Your Directors confirm:

- i) that in the preparation of the annual accounts, the applicable accounting standards have been followed along with proper explanation relating to material departures;
- ii) that your Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year March 31, 2017 and of the profit of the Company for the year;
- iii) that your Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;

IPCA PHARMACEUTICALS INC.

- iv) that your Directors have prepared the annual accounts on a going concern basis.
- v) that your Directors have laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and were operating effectively.
- vi) that your Directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

FIXED DEPOSIT

During the year under review, the Company has not accepted any fixed deposits within the meaning of Section 73 of the Companies Act, 2013.

PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS

The Company has not given any loans or guarantees or made any investment in any other Company.

AUDITORS, AUDIT REPORT AND AUDITED FINANCIAL STATEMENTS:

The Auditors' Report read with the notes to the accounts referred to therein are self-explanatory and therefore, do not call for any further comments.

PARTICULARS OF EMPLOYEES

Statement required under Section 197 of the Companies Act, 2013 read with rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (including any statutory modification(s) or re-enactment thereof for the time being in force).

Employed throughout the financial year:

Sr. No	Name	Designation	Qualification	Date of Employment	Exp Yr	Gross Remuneration	Age	Last Employment
1	Hasit Bhatt	President	B.Com, L.L.B., AICWA	01/04/2004	32 Yrs	Rs. 234.27 lacs	58 yrs	Vice President (Business Development) Ipca Laboratories Ltd., Mumbai

IPCA PHARMACEUTICALS INC.

ACKNOWLEDGEMENTS

Your Directors place on record their profound admiration and sincere appreciation of the continued hard work put in by employees at all levels. Your Directors also place on record their appreciation for the continued co-operation and support extended to the Company by the trade and the customers.

For and behalf of the Board

A handwritten signature in black ink that reads "Pranay Godha". The signature is written in a cursive style with a long horizontal stroke at the end.

Pranay Godha

Chairman


May 28, 2017

IPCA PHARMACEUTICALS INC., USA
Balance Sheet as at March 31, 2017

Particulars	Note Ref.	(₹ Lakhs)	(₹ Lakhs)	(₹ Lakhs)
		As at 31/03/2017	As at 31/03/2016	As at 01/04/2015
ASSETS				
(1) Non-current assets				
(a) Property, Plant and Equipment	1	631.45	681.18	674.29
(b) Capital work-in-progress		-	-	-
(c) Investment Property		-	-	-
(d) Goodwill		-	-	-
(e) Other Intangible assets		-	-	-
(f) Intangible assets under development		-	-	-
(g) Biological Assets other than bearer plants		-	-	-
(h) Financial Assets		-	-	-
(i) Investments		-	-	-
(ii) Trade receivables		-	-	-
(iii) Loans	2	4.33	4.43	4.18
(iv) Others		-	-	-
(i) Deferred tax assets (Net)		-	-	-
(j) Other Non-current assets		-	-	-
		635.78	685.61	678.47
(2) Current Assets				
(a) Inventories		-	-	-
(b) Financial Assets		-	-	-
(i) Investments		-	-	-
(ii) Trade receivables	3	14.76	123.77	177.02
(iii) Cash and cash equivalents	4	71.90	44.41	44.81
(iv) Bank balances other than (iii) above		-	-	-
(v) Loans	2	1.73	2.37	4.68
(vi) Others		-	-	-
(c) Current Tax Assets (Net)		-	-	-
(d) Other current assets		-	-	-
		88.39	170.55	226.51
Total Assets		724.17	856.16	904.98
EQUITY & LIABILITIES				
Equity				
(a) Equity Share capital	5	920.20	920.20	854.62
(b) Other Equity	6	(201.86)	(267.43)	(392.42)
		718.34	652.77	462.20
LIABILITIES				
(1) Non-current liabilities				
(a) Financial Liabilities		-	-	-
(i) Borrowings		-	-	-
(ii) Trade payables		-	-	-
(iii) Other financial liabilities		-	-	-
(b) Provisions		-	-	-
(c) Deferred tax liabilities (Net)		-	-	-
(d) Other Non-current liabilities		-	-	-
(2) Current liabilities				
(a) Financial Liabilities		-	-	-
(i) Borrowings	7	-	198.75	437.47
(ii) Trade payables	8	5.83	4.64	4.37
(iii) Other financial liabilities		-	-	-
(b) Other current liabilities		-	-	-
(c) Provisions		-	-	-
(d) Others	9	-	-	0.94
(e) Current Tax Liabilities (Net)		-	-	-
		5.83	203.39	442.78
Total Equity and Liabilities		724.17	856.16	904.98

Statement of Significant Accounting policies and Other Explanatory Notes form part of the Balance Sheet and Statement of Profit and Loss.

For and on behalf of the Board



Praraj Goyna
Chairman/Director

Place: Mumbai
Date: May 28, 2017

IPCA PHARMACEUTICALS INC., USA
Statement of Profit and Loss for the year ended 31st March, 2017

Particulars	Note Ref.	(₹ Lakhs) 2016-17	(₹ Lakhs) 2015-16
I Revenue from operations	10	504.40	571.02
II Other income	11	-	3.96
III Total Income (I+II)		<u>504.40</u>	<u>574.98</u>
IV Expenses			
Cost of materials consumed		-	-
Purchases of stock-in-trade		-	-
Changes in inventories of finished goods, Stock-in -Trade and work-in-progress		-	-
Employee benefits expense	12	300.32	328.98
Finance costs	13	0.60	7.12
Depreciation and amortisation expense	1	35.21	34.62
Other expenses	14	84.86	109.74
Total Expenses (IV)		<u>420.99</u>	<u>480.46</u>
V Profit/(loss) before exceptional items and tax (III-IV)		<u>83.41</u>	<u>94.52</u>
VI Exceptional items		-	-
VII Profit/ (loss) before tax (V-VI)		<u>83.41</u>	<u>94.52</u>
VIII Tax expense:			
(1) Current tax		-	-
(2) Deferred tax		-	-
IX Profit/ (loss) for the period from continuing operations (VII-VIII)		<u>83.41</u>	<u>94.52</u>
X Profit/ (loss) from discontinued operations			
XI Tax expense of discontinued operations		-	-
XII Profit/ (loss) from discontinued operations (after tax) (X-XI)		-	-
XIII Profit/ (loss) for the period (IX+XII)		<u>83.41</u>	<u>94.52</u>
XIV Other Comprehensive Income			
A (i) Items that will not be reclassified to profit or loss		-	-
(ii) Income tax relating to items that will not be reclassified to profit or loss		-	-
B (i) Items that will be reclassified to profit or loss			
Exchange difference in translating the financials statement of foreign operation		(17.83)	29.78
(ii) Income tax relating to items that will be reclassified to profit or loss		-	-
		<u>(17.83)</u>	<u>29.78</u>
XV Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period)		<u>65.58</u>	<u>124.31</u>
XVI Earnings per equity share (for continuing operation) :			
(1) Basic		-	-
(2) Diluted		-	-
Par Value		No Par value*	No Par value*

Statement of significant accounting policies and other explanatory notes form part of the balance sheet and statement of profit and loss

For and on behalf of the Board



Pralay Godha
Chairman/Director

Place: Mumbai
Date: May 28, 2017

IPCA PHARMACEUTICALS INC., USA
Cash flow statement for the year ended 31st March 2017

Particulars	(₹ Lakhs) 2016-17	(₹ Lakhs) 2015-16
CASH FLOW FROM OPERATING ACTIVITIES		
1. Net profit/(loss) before taxation	83.41	94.52
Adjustments for :		
Interest Income	(0.01)	(0.04)
Depreciation	35.21	34.62
Bank Charges	-	0.70
Finance charges	0.60	7.12
	<u>119.21</u>	<u>136.92</u>
2. Operating profit/(loss) before working capital changes		
Decrease/(Increase) in Receivables and Advances	109.75	55.31
Decrease/(Increase) in Inventory	-	-
Increase/(Decrease) in Current Liabilities	1.19	(0.67)
	<u>110.94</u>	<u>54.64</u>
Movement in Foreign currency translation reserve	(3.32)	(10.25)
3. Cash generated from operation (A)	<u>226.83</u>	<u>181.31</u>
CASH FLOW FROM INVESTING ACTIVITIES		
Interest Income	0.01	0.04
Sale/(Purchase) of Fixed Assets	-	(1.49)
	<u>0.01</u>	<u>(1.45)</u>
Net cash from / (used) in investing activities (B)		
CASH FLOW FROM FINANCING ACTIVITIES		
Issue of Share Capital	-	65.58
Repayment of Short Term Borrowing	(198.75)	(238.72)
Finance charges	(0.60)	(7.12)
	<u>(199.35)</u>	<u>(180.26)</u>
Net cash from / (used) in Financing activities (C)	<u>(199.35)</u>	<u>(180.26)</u>
Net increase/(decrease) in cash and cash equivalents (A + B + C)	<u>27.49</u>	<u>(0.40)</u>
Cash and cash equivalents at beginning of period	<u>44.41</u>	<u>44.81</u>
Cash and cash equivalents at end of period	<u>71.90</u>	<u>44.41</u>
Components of Cash and Cash equivalents:		
Cash in hand	71.90	44.41
Balance with Banks	<u>71.90</u>	<u>44.41</u>

For and on behalf of the Board


Pranay Godha
Chairman/Director

Place: Mumbai
Date: May 28, 2017

IPCA PHARMACEUTICALS INC.,USA

Statement of change in equity for the year ended March 31, 2017

(₹ Lakhs)

Particulars	Equity share capital	Reserves & Surplus		Other Reserves	Total
		Retained Earnings	Parent Contribution	Foreign Currency Translation reserve	
As at April 01,2015	854.62	(403.00)	10.57		462.20
Profit for the period	-	94.52	-	-	94.52
Contribution for the period	-	-	0.69	-	0.69
Exchange difference in transalting the financial statement of foreign operation	-	-	-	29.78	29.78
Shares issued during the year	65.58	-	-	-	65.58
	-	-	-	-	-
Balance as on March 31, 2016	920.20	(308.47)	11.26	29.78	652.77
Profit for the period	-	83.41	-	-	83.41
Exchange difference in transalting the financial statement of foreign operation	-	-	-	(17.83)	(17.83)
	-	-	-	-	-
Balance as on March 31, 2017	920.20	(225.06)	11.26	11.95	718.34

For and on behalf of the Board



Pranay Godha
Chairman/Director

Place: Mumbai

Date: May 28, 2017

IPCA PHARMACEUTICALS INC.,USA

Statement of Significant Accounting policies and Other Explanatory Notes

ACCOUNTING POLICIES

a) Accounting Convention

The Financial Statements have been prepared to comply in all material respects with the notified Indian accounting standards (Ind AS) prescribed under Section 133 of the Act read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016. The financial statements have been prepared under the historical cost convention, on an accrual basis of accounting.

For all periods upto and including the year ended March 31, 2016 the Company prepared its financial statements in accordance with accounting standards notified under the section 133 of the Companies Act, 2013 read together with paragraph 7 of the Companies (Accounts) Rules, 2014 (Previous GAAP).

The Company presents assets and liabilities in the balance sheet based on current/non-current classification.

An asset is current when :

- It is expected to be realised or intended to be sold or consumed in normal operating cycle or
- It is held primarily for the purpose of trading or
- It is expected to be realised within twelve months after the reporting period, or
- It is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period

All other assets are classified as non-current.

A liability is current when :

- It is expected to be settled in normal operating cycle or
- It is held primarily for the purpose of trading or
- It is due to be settled within twelve months after the reporting period, or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period

The Company classifies all other liabilities as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities.

The accounting policies adopted in the preparation of financial statements are consistent with those used in the previous year.

b) Conversion in to Indian Rupees

The translation of financial statements into Indian Rupees is done in accordance with Ind AS 21 (Revised) "Effects of Changes in Foreign Exchange" notified by the Companies (Accounting Standards) Rules 2015. The resultant Foreign Currency Translation Reserve is shown separately under other comprehensive reserves forming part of Other Equity.

The Assets and Liabilities are translated at closing rate except share capital which is translated at the rate as on transaction date. The income and expenditure are translated at a rate nearing the average rate during the year.

c) Property, Plant and Equipment: The Property, plant and equipment existing on the date of transition are accounted on deemed cost basis by applying para D7AA in accordance with the exemption provided in Ind AS 101 " First-time Adoption of Indian Accounting Standards" at previous GAAP carrying value.

d) Depreciation: Depreciation is being provided based on estimated useful life using straight-line method.

e) Inventories: Inventories are valued on first in first out (FIFO) method at cost or net realizable value (NRV), whichever is lower.

f) Revenue

i) Revenue from sale of service is recognized when the services are rendered.

ii) Interest income is recognised on time proportion method basis taking into account the amount outstanding and rate applicable. It is recognised only when ultimate collection is certain.

g) Taxation

Tax expenses comprise Current Tax and Deferred Tax.:

i) Current Tax:

Current Tax is calculated as per the income tax law prevailing in USA. Since the Company has accumulated losses, no Income Tax provision has been made for Federal .However, provision for NJ State Tax has been made.

ii) Deferred Tax:

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

h) Cash and Cash Equivalents: Cash and cash equivalents in the Balance Sheet comprise cash at bank,cheques on hand, cash in hand and short term investments with an original maturity of three months or less.

i) Provisions, Contingent Liabilities and Contingent Assets

i) A provision is recognised when an enterprise has a present obligation as a result of past event; it is probable that an outflow of resources will be required to settle the obligation, in respect of which a reliable estimate can be made. Provisions are not discounted to its present value and are determined based on best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimates.

ii) Contingent Liabilities are not recognised but disclosed in notes to accounts.

Note 1

Property, Plant and Equipment

(₹ lakhs)

Particulars	Gross Block							Depreciation						Net Block			
	As on 01/04/2015	Additions	Foreign Exchange fluctuation Reserve	As on 01/04/2016	Additions	Foreign Exchange fluctuation Reserve	As on 31/03/2017	As on 01/04/2015	For the year	Foreign Exchange fluctuation Reserve	As on 01/04/2016	For the year	Foreign Exchange fluctuation Reserve	As on 31/03/2017	As on 31/03/2017	As on 31/03/2016	As on 01/04/2015
Building	668.59	-	40.17	708.76	-	(16.33)	692.43	24.31	25.41	1.83	51.55	26.05	(2.07)	75.54	616.89	657.21	644.280
Furniture and Fixtures	62.77	1.49	3.77	68.03	-	(1.57)	66.46	36.06	7.48	2.27	45.81	7.39	(1.30)	51.90	14.56	22.22	26.710
Office Equipment	21.80	-	1.31	23.11	-	(0.53)	22.58	18.50	1.73	1.13	21.36	1.77	(0.55)	22.58	-	1.75	3.300
Total	753.16	1.49	45.25	799.90		(18.43)	781.47	78.87	34.62	5.23	118.72	35.21	(3.91)	150.02	631.45	681.18	674.29
Previous Year	714.88	5.53	32.75	753.16	1.49	45.25	799.90	42.72	33.40	2.75	78.87	34.62	5.23	118.72	681.18	674.29	672.16

2 Financial Assets - Loans						
Particulars	As at 31/03/2017 (₹ Lakhs)		As at 31/03/2016 (₹ Lakhs)		As at 01/04/2015 (₹ Lakhs)	
	Current	Non-Current	Current	Non-Current	Current	Non-Current
(a) Security Deposit	-	4.33	-	4.43	1.40	4.18
(b) Prepaid expenses	1.73	-	2.37	-	3.28	-
Total	1.73	4.33	2.37	4.43	4.68	4.18

3 Financial Assets - Trade receivables (Unsecured, at amortised cost)						
Particulars	As at 31/03/2017 (₹ Lakhs)		As at 31/03/2016 (₹ Lakhs)		As at 01/04/2015 (₹ Lakhs)	
	Current	Non-Current	Current	Non-Current	Current	Non-Current
(a) Unsecured, considered good	14.76	-	123.77	-	177.02	-
Total	14.76	-	123.77	-	177.02	-

4 Financial Assets - Cash & Cash Equivalents						
Particulars	As at 31/03/2017 (₹ Lakhs)		As at 31/03/2016 (₹ Lakhs)		As at 01/04/2015 (₹ Lakhs)	
	Cash on hand	-	-	-	-	0.16
Balances with banks	71.90	-	44.41	-	44.65	-
Cheques, drafts on hand	-	-	-	-	-	-
Fixed deposit with bank	-	-	-	-	-	-
Total	71.90	-	44.41	-	44.81	-

5 Equity Share Capital						
Particulars	As at 31/03/2017 (₹ Lakhs)		As at 31/03/2016 (₹ Lakhs)		As at 01/04/2015 (₹ Lakhs)	
	No. of shares	No Par value*	No. of shares	No Par value*	No. of shares	No Par value*
Face Value						
Class of Shares						
Authorised Capital*						
Equity Shares fully paid						
Issued, Subscribed and Paid up Capital						
Issued & Subscribed & Paid up	1,975,000	920.20	1,975,000	920.20	1,875,000	854.62
Total	1,975,000	920.20	1,975,000	920.20	1,875,000	854.62

* In accordance with the governing law of the country where the company is incorporated there is no provision for authorized capital and par value. The same is therefore not disclosed.

Disclosures:

i) Reconciliation of Shares

Particulars	As at 31/03/2017		As at 31/03/2016		As at 01/04/2015	
	No. of shares	(₹ Lakhs)	No. of shares	(₹ Lakhs)	No. of shares	(₹ Lakhs)
Shares outstanding at the beginning of the year	1,975,000	920.20	1,875,000	854.62	1,875,000	854.62
Shares Issued during the year	-	-	100,000	65.58	-	-
Shares outstanding at the end of the year	1,975,000	920.20	1,975,000	920.20	1,875,000	854.62

ii) Details of Shareholding in excess of 5%

Name of Shareholder	As at 31/03/2017		As at 31/03/2016		As at 01/04/2015	
	No. of shares	%	No. of shares	%	No. of shares	%
Ipcalaboratories Ltd	26,944	100.00	26,944	100.00	26,944	100.00

6 Other Equity

Particulars	As at 31/03/2017 (₹ Lakhs)		As at 31/03/2016 (₹ Lakhs)		As at 01/04/2015 (₹ Lakhs)	
	(a) Retained Earnings	(225.06)	-	(308.47)	-	(403.00)
(b) Parents Contribution	11.26	-	11.26	-	10.57	-
(c) OCI Reserves						
- Foreign Currency Translation Reserve	11.95	-	29.78	-	-	-
Total	(201.85)	-	(267.43)	-	(392.42)	-

7 Financial Liabilities - Borrowings

Particulars	As at 31/03/2017 (₹ Lakhs)		As at 31/03/2016 (₹ Lakhs)		As at 01/04/2015 (₹ Lakhs)	
	Unsecured Loans:					
Short Term Loans from Banks	-	-	198.75	-	437.47	-
Total	-	-	198.75	-	437.47	-

8 Financial Liabilities - Trade Payables

Particulars	As at 31/03/2017 (₹ Lakhs)		As at 31/03/2016 (₹ Lakhs)		As at 01/04/2015 (₹ Lakhs)	
	Trade Payables					
- Micro Small and Medium Enterprises	-	-	-	-	-	-
- Others	5.83	-	4.64	-	4.37	-
Total	5.83	-	4.64	-	4.37	-

9 Other Non-financial Liabilities

Particulars	As at 31/03/2017 (₹ Lakhs)		As at 31/03/2016 (₹ Lakhs)		As at 01/04/2015 (₹ Lakhs)	
	Duties & taxes payables	-	-	-	-	0.94
Total	-	-	-	-	0.94	-

IPCA PHARMACEUTICALS INC.,USA

Notes to financial statements as at and for the year ended March 31, 2017

10 Revenue From Operation

Particulars	2016-17 (₹ Lakhs)	2015-16 (₹ Lakhs)
Sale of products	-	-
Sale of Service	504.40	571.02
Other Operating revenue	-	-
Total	504.40	571.02

11 OTHER INCOME

Particulars	2016-17 (₹ Lakhs)	2015-16 (₹ Lakhs)
Interest received	0.01	0.04
Misc Income	-	3.92
Total	0.01	3.96

12 EMPLOYEE BENEFITS EXPENSE

Particulars	2016-17 (₹ Lakhs)	2015-16 (₹ Lakhs)
Salaries	260.85	279.00
Staff Welfare	23.21	30.03
Others	16.26	19.95
Total	300.32	328.98

13 FINANCE COST

Particulars	2016-17 (₹ Lakhs)	2015-16 (₹ Lakhs)
Finance charges	0.60	7.12
Total	0.60	7.12

14 Other Expenses

Particulars	2016-17 (₹ Lakhs)	2015-16 (₹ Lakhs)
Travelling and Boarding expenses	3.31	17.60
Rent*	31.70	31.33
Insurance	4.45	4.18
Rates and taxes	16.88	20.37
Printing & Stationery	0.01	0.44
Repairs & Maintenance		
- Building	5.01	6.20
Vehicle Expenses	5.83	9.83
Communication expenses	6.37	7.82
Professional charges	2.68	-
Office Supplies	1.36	0.93
Audit Fees	3.35	3.27
Books and Subscription	0.92	1.57
Bank charges	1.24	1.17
Bank charges (Ind AS)	-	0.69
Security charges	0.72	0.66
Sales and Marketing Expenses	-	2.45
Miscellaneous Expenses	1.03	1.23
PER STATEMENT OF PROFIT & LOSS	84.86	109.74

IPCA PHARMACEUTICALS INC., USA

Notes to financial statements as at and for the year ended March 31, 2017

15 Disclosure as required by IND AS 24 "Related Party Disclosures" notified by the Companies (Accounting Standards) Rules 2015.

Relationship:	Country
A. Entities where control exists	
Shareholders of Ipca Pharmaceuticals Inc. Ipca Laboratories Limited.	India
B. Key Management Personnel	
Mr. Hasit V. Bhatt- President	USA
Mr. Pranay Godha-Director	India

Transactions (₹ lakhs)

Description	Entities where control exists Holding Company	Key Management Personnel	Total
Remuneration			
Hasit Bhatt	-	234.27	234.27
(Previous Year)	-	196.07	197.07
Total	-	234.27	234.27
(Previous Year)	-	196.07	197.07
Goods and Services Purchased			
Ipca Laboratories Limited	-	-	-
(Previous Year)	-	-	133.98
Total	-	-	-
(Previous Year)	-	-	133.98
Service Charges			
Ipca Laboratories Limited	504.40	-	504.40
(Previous Year)	571.02	-	678.54
Total	504.40	-	504.40
(Previous Year)	571.02	-	678.54
Reimbursement of expenditure			
Ipca Laboratories Limited	-	-	-
(Previous Year)	19.28	-	26.97
Total	-	-	-
(Previous Year)	19.28	-	26.97
Shares Issued			
Ipca Laboratories Limited	-	-	-
(Previous Year)	65.58	-	65.58
Total	-	-	-
(Previous Year)	65.58	-	65.58
Balances as on 31st March 2017			
Receivable			
Ipca Laboratories Limited	14.76	-	14.76
(Previous Year)	123.77	-	123.77
Total	14.76	-	14.76
(Previous Year)	123.77	-	123.77
Payable			
Ipca Laboratories Limited	-	-	-
(Previous Year)	-	-	-
Total	-	-	-
(Previous Year)	-	-	-

16 Earning per share is not given since shares carry no par value.

17 Commitments and contingencies

Particulars	31st March' 2017 (₹ lakhs)	31st March' 2016 (₹ lakhs)
The Company has one lease commitments for its office which expires on 31st March 2017.	37.45	28.44

18 Prior period comparatives

Previous year's figures have been regrouped or rearranged where ever necessary.

19 The annual accounts have been prepared on going concern basis.

20 The Company is 100% subsidiary of Ipca Laboratories Limited. The accounts have been prepared and restated in Indian Rupees for the purpose of attachment to the accounts of the holding company to comply with the provisions of Indian Companies Act.

21 The Balance Sheet, Statement of Profit and Loss, Statement of Changes in Equity, Cash Flow Statement, Statement of significant accounting policy and other explanatory notes form an integral part of the financial statements of the company for the year ended on March 31, 2017.

For and on behalf of the Board


Pranay Godha
Chairman/Director

Place: Mumbai
Date: May 28, 2017